Dr. Stephen Robbins
March 2021Research at the Lady Davis Institute

A year with COVID-19: The therapeutic pipeline

Dr. Stephen Robbins, new Director of the Lady Davis Institute, and Dr. Donna Senger, of the LDI’s Cancer Axis, have received up to $6.7 million in federal support for a drug candidate that could bring relief to hospitalized patients with a severe case of COVID-19.

READ MORE →
Dr. Magali Lecavalier-Barsoum consults with Technologist Dennis Ip about the linear accelerator that provides radiation therapy to cancer patients in the Division of Radiation Oncology. (Click on photo to enlarge.)
January 2021Telehealth

Telehealth plays key role in Radiation Oncology, even though treatment is provided in person

Although radiation therapy for cancer must be administered in person, the Division of Radiation Oncology is making extensive use of telehealth to provide support to patients and keep staff in the loop.

READ MORE →
Dr. Samy Suissa
October 2016Research at the Lady Davis Institute

Mandate renewed for Canada-wide drug safety consortium based at the LDI

A renewed five-year mandate has been granted to a national consortium on prescription drug safety that is headquartered in the Lady Davis Institute at the JGH.

READ MORE →